Home › Funds › Spyglass Capital Management LLC › ASND

Spyglass Capital Management LLC position in ASND

ASCENDIS PHARMA A/S · Health Care

Spyglass Capital Management LLC reported holding 151,549 shares of ASND (ASCENDIS PHARMA A/S) in its Q3 2026 13F filing — a position valued at US$34.5M, representing 2.02% of its reported portfolio and ranking #25 among its reported holdings. Spyglass Capital Management LLC has disclosed ASND holdings in 10 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)151.55K sh
Reported value held$34.53M
Portfolio Weight2.02%
First reportedQ3 2023
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Spyglass Capital Management LLC's ASND position evolved

Spyglass Capital Management LLC first disclosed a stake in ASND in Q3 2023 at 614,618 shares (US$57.6M). The position peaked in Q3 2024 at 652,841 shares, worth US$97.5M. Across 10 filings, Spyglass Capital Management LLC increased the stake 3 time(s), trimmed it 5 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 151,549 shares valued at US$34.5M — a reduction of -63,849 shares quarter over quarter.. Notable position changes include a 41% trim in Q2 2026 (shares fell 15% over the following quarter), a 30% trim in Q3 2026 (shares rose 21% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 614.62K $57.55M New
Q4 2023 539.95K $68.01M Reduce
Q1 2024 614.11K $92.83M Add
Q2 2024 662.89K $90.40M Add
Q3 2024 652.84K $97.48M Reduce
Q3 2025 388.65K $77.27M New
Q4 2025 415.55K $88.61M Add
Q1 2026 367.97K $84.17M Reduce
Q2 2026 215.40K $57.45M Reduce
Q3 2026 151.55K $34.53M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ASND and 13F data

ASND (ASCENDIS PHARMA A/S) is a Health Care company. 37 other funds we track also report a position in ASND — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$2.74B), T. Rowe Price Investment Management, Inc. (US$1.80B), Avoro Capital Advisors LLC (US$1.36B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ASND

All ASND fund holders →

FAQ

How long has Spyglass Capital Management LLC held ASND?

Spyglass Capital Management LLC has disclosed ASND holdings in 10 of the last 13 reported quarters, going back to Q3 2023.

What is Spyglass Capital Management LLC's current position in ASND?

As of Q3 2026, Spyglass Capital Management LLC holds 151.55K shares of ASND (ASCENDIS PHARMA A/S), valued at $34.53M, representing 2.02% of its reported portfolio and ranking #25.

Has Spyglass Capital Management LLC been buying or selling ASND?

In the latest 13F filing (Q3 2026), Spyglass Capital Management LLC reduced its position in ASND. The position peaked in Q3 2024 at 652.84K shares.

Which other funds hold ASND?

Other major institutional holders of ASND include RA CAPITAL MANAGEMENT, L.P., T. Rowe Price Investment Management, Inc., Avoro Capital Advisors LLC, among 37 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.